Ardelyx, Inc. (ARDX)

NGM – Цена в реальном времени. Валюта: USD

3.97

+0.03 (0.76%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

3.97

0.00 (0.00%)

После закрытия: Aug 12, 2026, 4:53 PM EDT

12.08.2026

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force to convert demand into realized revenue.

07.08.2026

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

07.08.2026

New Strong Sell Stocks for August 7th

ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.

07.08.2026

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates

Ardelyx (ARDX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.

07.08.2026

Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

06.08.2026

Ardelyx Q2 Earnings Call Highlights

Ardelyx NASDAQ: ARDX reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company's largest quarterly revenue total to date. The company lowered its 2026 revenue outlook for IBSRELA while maintaining its forecast for XPHOZAH, citing increased payer restrictions affecting patient access to IBSRELA.

Видео

No Data

There is no data to display

Ardelyx, Inc. (ARDX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ardelyx, Inc. (ARDX)

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

New Strong Sell Stocks for August 7th

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates

Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics

Ardelyx Q2 Earnings Call Highlights

Видео

No Data

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

New Strong Sell Stocks for August 7th

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates

Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics

Ardelyx Q2 Earnings Call Highlights

Видео

No Data

Search stocks

Ardelyx, Inc. (ARDX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ardelyx, Inc. (ARDX)

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

New Strong Sell Stocks for August 7th

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates

Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics

Ardelyx Q2 Earnings Call Highlights

Видео

No Data

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

New Strong Sell Stocks for August 7th

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates

Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics

Ardelyx Q2 Earnings Call Highlights

Видео

No Data